BioWorld Asia

Feb. 4, 2004

Cyclacel's Fourth Round Gets $39M For Cell Cycle Inhibitors

LONDON - Cyclacel Ltd. raised £21.3 million (US$39 million) in an oversubscribed fourth round of private funding, bringing its total private equity raised to date to $123 million. (BioWorld International) Read More

Acambis Moving R&D Core To U.S.,Cutting Work Force By 40

Predatory Bacterium Could Hold Key To Antibiotic Treasure Trove

With GLP-2 In Osteoporosis Focus, Sanos Raises $10M

PharmaMar Cutting Staff To Conserve Cash For Yondelis

ExonHit Raises Additional EUR8.3M; Now Has Cash To Last Into 2006

Another European Request For Lifting GMO Moratorium

Dissent With Partner Spurs Cutbacks At Micromet AG

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...